BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 26621054)

  • 1. Active surveillance for prostate cancer.
    Romero-Otero J; García-Gómez B; Duarte-Ojeda JM; Rodríguez-Antolín A; Vilaseca A; Carlsson SV; Touijer KA
    Int J Urol; 2016 Mar; 23(3):211-8. PubMed ID: 26621054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evidence review of active surveillance in men with localized prostate cancer.
    Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
    Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The experience of adults who choose watchful waiting or active surveillance as an approach to medical treatment: a qualitative systematic review.
    Rittenmeyer L; Huffman D; Alagna M; Moore E
    JBI Database System Rev Implement Rep; 2016 Feb; 14(2):174-255. PubMed ID: 27536798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
    Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
    Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
    J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.
    Simpkin AJ; Tilling K; Martin RM; Lane JA; Hamdy FC; Holmberg L; Neal DE; Metcalfe C; Donovan JL
    Eur Urol; 2015 Jun; 67(6):993-1005. PubMed ID: 25616709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latest Evidence on the Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Insignificant Prostate Cancer: A Systematic Review.
    Cantiello F; Manno S; Russo GI; Cimino S; Privitera S; Morgia G; Cicione A; Damiano R
    Anticancer Agents Med Chem; 2018; 18(7):925-930. PubMed ID: 29303080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LOW RISK PROSTATE CANCER: ACTIVE TREATMENT OR ACTIVE SURVEILLANCE?
    Tomašković I
    Acta Clin Croat; 2015 Sep; 54(3):337-44. PubMed ID: 26666105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active Surveillance for Low-risk Prostate Cancer: Are All Criteria Similar?
    Cimino S; Privitera S; Favilla V; Cantiello F; Manno S; Cicione A; Damiano R; Russo GI; Morgia G
    Anticancer Agents Med Chem; 2018; 18(7):958-963. PubMed ID: 29692262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer.
    Goldberg H; Klaassen Z; Chandrasekar T; Fleshner N
    Curr Opin Urol; 2018 Jan; 28(1):46-54. PubMed ID: 29028765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer - active surveillance as a management option.
    Yaxley J; Yaxley J; Gardiner R; Yaxley W
    Aust Fam Physician; 2013; 42(1-2):74-6. PubMed ID: 23529468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
    Botejue M; Abbott D; Danella J; Fonshell C; Ginzburg S; Guzzo TJ; Lanchoney T; Marlowe B; Raman JD; Smaldone M; Tomaszewski JJ; Trabulsi EJ; Uzzo RG; Reese AC
    J Urol; 2019 May; 201(5):929-936. PubMed ID: 30720692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
    Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
    BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
    Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
    BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
    Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
    J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation.
    Amin MB; Lin DW; Gore JL; Srigley JR; Samaratunga H; Egevad L; Rubin M; Nacey J; Carter HB; Klotz L; Sandler H; Zietman AL; Holden S; Montironi R; Humphrey PA; Evans AJ; Epstein JI; Delahunt B; McKenney JK; Berney D; Wheeler TM; Chinnaiyan AM; True L; Knudsen B; Hammond ME
    Arch Pathol Lab Med; 2014 Oct; 138(10):1387-405. PubMed ID: 25092589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study.
    Scholz MC; Groom MK; Kaddis AJ; Strum SB; Jennrich RI; Bahn DK; Chang PJ; Becker LK; Lam RY
    Prostate; 2013 Jan; 73(1):83-8. PubMed ID: 22753276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.